Intra-Abdominal Instillation Of Fresh Frozen Plasma Versus Corticosteroids In Prevention Of Recurrent Attacks Of Adhesive Intestinal Obstruction: A 2 Years' Experience Clinical Study
Condition(s) studied
Investigational drug(s) / intervention(s)
intra-abdominal instillation of corticosteroids: after adhesiolysis, peritoneal lavage with diluted corticosteroids will be instillated intra-abdominally
intra-abdominal instillation of fresh frozen plasma: after adhesiolysis, peritoneal lavage with diluted FFP will be instillated intra-abdominally
Study summary
Adhesive Intestinal obstruction is an inevitable complication of abdominal surgery with significant morbidity associated with poor quality of life and predispose to repeated hospitalization. Most of them (73% - 90%) can be managed conservatively.Despite advances in surgery, 15to 30% require surgical intervention primarily or due to failure of conservative management. Because of the nature of the disease recurrence has been estimated to be 30%.Many attempts to prevent formation of postoperative adhesions have been tried. In this trial, we will study the effect of corticosteroids and FFP in prevention of adhesive small bowel obstruction recurrence for follow up of 2 years duration.
Eligibility
Primary outcome measure(s)
- intestinal obstruction — from 1 day to 2 years post operative
intestinal obstruction is detected if the patient had constipation and vomiting with ultrasound showing dilated bowel and to and fro movement and the plain erect shows multiple air fluid levels - bowel injury — from 1 day to 2 years post operative
bowel injury will be detected if intestinal contents present in the drain or wound - wound infection — from 1 day to 2 weeks post-operative
wound infection is detected if there is pus in the drain or wound
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Faculty of Medicine | Zagazig | Sharqia Province | |
| Zagazig University Hospitals | Zagazig | zagazig |
More Zagazig University trials in Egypt
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06859307 on ClinicalTrials.gov ↗ ← All trials in Egypt